Search

FDA Approves Pradaxa, Marking a Major Milestone to Reduce the Risk of Stroke in Patients with Non-Valvular Atrial Fibrillation

Update on LUME-Meso Clinical Trial

Click here to read an update on the LUME-Meso clinical trial, comparing nintedanib with other treatment options for malignant pleural mesothelioma.

FDA Approves SPIRIVA® RESPIMAT® (tiotropium bromide) for Asthma | BI US

FDA approval of SPIRIVA RESPIMAT for maintenance treatment of asthma in patients 12 and older marks a new class of treatment with once-daily prescriptions.

Pradaxa® (dabigatran etexilate mesylate) Capsules Gains Preferred Formulary Status with AARP®, Nation's Largest Provider of Medicare Part D Coverage

BI USA Recognized as Best Place to Work for LGBTQ+ Equality

Regulatory Affairs

Read more on BI's two-year fellowship within Regulatory Affairs. The Fellow will obtain in-depth and hands-on experience in regulatory strategy.

Annual Declaration of Boehringer Ingelheim Corporation’s compliance with its Comprehensive Compliance Program.

The Role of Endocrinologists and PCPs in Diagnosing Chronic Kidney Disease

Mohamed Eid shares his perspective on the role endocrinologists and primary care professionals play in diagnosing chronic kidney disease.

An Employee’s Commitment to Ensuring Access to Medicines

New Analyses Showed Consistent Efficacy of OFEV® (nintedanib) Across Various Patient Populations with Idiopathic Pulmonary Fibrosis (IPF)

Boehringer Ingelheim and Eli Lilly and Company submit new drug application to FDA for empagliflozin, an investigational type 2 diabetes treatment

Giving Back to Those Who Serve Our Country

Helping a Local Community in a Time of Need

Leadership insights about our focus on patient centricity

Read about our patient-centric approach in discovering and developing medicines that transform patients’ lives from the point of view of Keri Yale, our head of patient centricity and engagement

Big Little Things: In cancer, small things make a big impact

Little things can be a big deal when you are living with or treating cancer. “Big Little Things” celebrates the small things that have a big impact.

Identifying Risk Factors to Improve Outcomes in Chronic Kidney Disease

What to Expect from Your Vaccine | Boehringer Ingelheim US

Read more on how horse owners are encouraged to schedule a wellness exam with their veterinarians, including annual equine vaccinations.

Federal and State Laws

KDIGO’s 2024 Updated Guidelines Re-Emphasize Commitment to Comprehensive Testing for CKD

Mohamed Eid shares his thoughts on the updated KDIGO clinical practice guidelines, published in 2024, and the need for guidelines-directed care for CKD.

Orphan Drug Designation Granted to Nintedanib for Treatment of Systemic Sclerosis, including Associated Interstitial Lung Disease

Biosimilar Candidate to Humira® Accepted For Review | BI US

Boehringer Ingelheim announced today that its adalimumab biosimilar candidate to Humira®, has been accepted for regulatory review by the EMA and the FDA.

Creating an Inclusive Workplace for Employees with Disabilities

STIOLTO® RESPIMAT® (tiotropium bromide) Available in US | BI US

Read more about the newly available medication for COPD, STIOLTO RESPIMAT, proven to support both treatment and management of the disease.

How Much Do You Know About PPID? | Boehringer Ingelheim US

Click here to find out more about some of the common misconceptions you might have about pituitary pars intermedia dysfunction (PPID).

New Data Shows OFEV® (nintedanib) Efficacy is Sustained Long-term with No New Safety Signals in Patients with IPF

About Us

Human Health

Animal Health

Science & Innovation

Partnering

Careers